Form 8-K - Current report:
SEC Accession No. 0001437749-24-034922
Filing Date
2024-11-13
Accepted
2024-11-13 16:21:51
Documents
23
Period of Report
2024-11-13
Items
Item 2.02: Results of Operations and Financial Condition
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K dmtp20241113_8k.htm   iXBRL 8-K 38608
2 EXHIBIT 99.1 ex_747437.htm EX-99.1 212407
3 EXHIBIT 99.2 ex_747438.htm EX-99.2 4425
8 a01.jpg GRAPHIC 75842
9 a02.jpg GRAPHIC 71758
10 a03.jpg GRAPHIC 74068
11 a04.jpg GRAPHIC 90581
12 a05.jpg GRAPHIC 77036
13 a06.jpg GRAPHIC 62997
14 diamedicalogo.jpg GRAPHIC 6910
  Complete submission text file 0001437749-24-034922.txt   1038100

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA dmac-20241113.xsd EX-101.SCH 3410
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE dmac-20241113_def.xml EX-101.DEF 11030
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE dmac-20241113_lab.xml EX-101.LAB 14743
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE dmac-20241113_pre.xml EX-101.PRE 11135
26 EXTRACTED XBRL INSTANCE DOCUMENT dmtp20241113_8k_htm.xml XML 2731
Mailing Address 301 CARLSON PARKWAY SUITE 210 MINNEAPOLIS MN 55305
Business Address 301 CARLSON PARKWAY SUITE 210 MINNEAPOLIS MN 55305 (763) 496-5454
DiaMedica Therapeutics Inc. (Filer) CIK: 0001401040 (see all company filings)

EIN.: 000000000 | State of Incorp.: Z4 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36291 | Film No.: 241454638
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)